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Abstract 22 
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with poor survival. There is an urgent 23 
need to better diagnose and monitor IPF patients as new treatments which slow down disease 24 
progression are now available. Exhaled breath condensate (EBC) is easily and non-invasively 25 
collected, but analysis of potential biomarkers is difficult due to low concentrations and 26 
methodological limitations. We used a non-targeted metabolomics approach to identify discriminatory 27 
metabolic profiles that distinguish IPF patients from healthy controls. 28 
For the pilot study set, we collected EBC from 10 stable IPF patients and 10 lung healthy controls. 29 
Samples were analyzed by ultra high-performance liquid chromatography coupled to high-resolution 30 
mass spectrometry (UHPLC-HRMS) in positive and negative ion mode. After data processing and 31 
statistical analysis, 58 metabolites were found to be discriminative between IPF patients and controls 32 
in the positive ion mode. One metabolite candidate m/z = 341.3514 at a retention time of 9.94 min was 33 
2.5-fold up-regulated in IPF patients compared to healthy controls and validated in a second set of 34 
eight IPF patients and healthy controls. The identity of this metabolic feature still remains elusive. 35 
Our preliminary results identified a distinguished EBC profile of IPF patients compared to controls. 36 
Although these results need to be confirmed in additional individuals, EBC sampling for diagnosis 37 
and/or monitoring of IPF patients is a promising, new method, which should be further explored. The 38 
EBC samples have been obtained within the clinical trial NCT02173145 at baseline. 39 
 40 
 41 
 42 
 43 
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1. Introduction 44 
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease affecting mainly men over 60 years 45 
[1]. Patients present with unspecific clinical symptoms like worsening dyspnea during exercise and 46 
dry cough [1]. Clinical course and prognosis vary, ranging from slow progression to rapid disease 47 
deterioration which ultimately leads to death, on average after two to three years [1, 2]. Diagnosis of 48 
IPF requires a radiological and/or histological usual interstitial pneumonia (UIP) pattern and exclusion 49 
of known causes for interstitial lung disease (ILD), which might impact treatment decisions [1]. 50 
Invasive diagnostic procedures, including bronchoscopy and surgical lung biopsy are often needed for 51 
a confident diagnosis, but can be associated with high interventional risks, especially in patients 52 
suffering from severe respiratory impairment and hypoxia [3]. In addition to diagnostic challenges, the 53 
clinical course of the disease is unpredictable [2], treatment options are limited [4-6] and individual 54 
treatment response is difficult to assess. Although new medications are in use, which slow down lung 55 
functional decline, cure is still impossible and lung transplantation remains the ultimate option for few 56 
selected patients [4, 5]. Non-invasive diagnostic and monitoring tools are urgently needed for a safer 57 
and more efficient approach to IPF diagnosis, to predict the course of disease and monitor treatment 58 
response. A promising solution might be the identification of new biomarkers by exhaled breath 59 
analysis. [7].  60 
Exhaled breath condensate (EBC) is a non - invasively collected biofluid of the respiratory tract. EBC 61 
contains particles from the airway that enter EBC from the gas phase or from the alveolar lining fluid 62 
[8, 9]. Similar to blood or urine, EBC represents a matrix from which biomarkers may be identified. 63 
Breath monitoring by EBC sampling is simple and due to its non-invasiveness a particularly promising 64 
option to collect biological samples from patients with respiratory impairment. Over the last years, 65 
non-invasive methods to diagnose and monitor lung pathologies have gained increasing interest [10]. 66 
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In clinical practice NO in exhaled breath of asthma patients is commonly measured to evaluate 67 
treatment response [11]. Investigations of EBC in several lung diseases such as asthma [11], chronic 68 
obstructive pulmonary disease [12-14], cystic fibrosis [15], lung cancer [16] and interstitial lung 69 
diseases [11, 17] are ongoing. Different biomarker patterns in patients with smoking related lung 70 
diseases and healthy smokers were identified by analyzing EBC samples [18-21] and an individual 71 
metabolomic breath print is postulated [7]. 72 
The main advantage of EBC is its non-invasive collection. However, the use of EBC in clinical 73 
practice is still limited by the difficulties in analysis of its composition [22]. As EBC contains highly 74 
diluted molecules analytic biochemistry assays are difficult to perform. In this study, we investigated 75 
EBC by ultra high-performance liquid chromatography coupled to high-resolution mass spectrometry 76 
(UHPLC-HRMS), which has been recently suggested as a sensitive and selective technique to identify 77 
biomarkers in EBC [23].  78 
2. Materials and Methods 79 
2.1 Study participants 80 
All patients were recruited from the ILD clinic at the Department for Pulmonary Medicine, Inselspital, 81 
Bern University Hospital, Bern, Switzerland. Main inclusion criterion for patients was definitive or 82 
probable IPF diagnosis [1]. Definitive or possible UIP patterns were diagnosed on high resolution 83 
chest CT scans and, if available, UIP was confirmed on lung biopsy. Secondary causes for lung 84 
fibrosis were excluded and cases assessed by experienced ILD clinicians, radiologists, and 85 
pathologists during multidisciplinary discussion according to the current diagnostic standards [1]. 86 
Mortality risk was estimated by the GAP index and staging system, which includes gender, age, forced 87 
vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) [24]. Healthy 88 
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volunteers without a history of chronic lung disease were recruited, age ranged between 61 and 86 89 
years. EBC was collected from all patients and healthy controls after they signed informed consent. 90 
The EBC samples from IPF patients have been obtained within the clinical trial NCT02173145 at 91 
baseline. The study was performed according to human research law and approved by the local ethics 92 
committee (KEK 002/14, 246/15). 93 
 94 
2.2 EBC Collection 95 
EBC was collected using the Ecoscreen EBC collecting device from Erich Jaeger, Hoechberg, 96 
Germany, according to the manufacturer’s instructions and the ATS/ERS methodological 97 
recommendations for EBC collection [9]. All participants were advised not to eat at least one hour 98 
before EBC collection. The cooling device was precooled (-15°C to -20°C). A common blotting paper 99 
was placed inside the mouth piece just before the air enters the cooling chamber to reduce 100 
contamination with saliva. Participants sat upright, wore a nose clip and performed tidal breathing 101 
continuously for 10 minutes. Through cooling and condensation 3-5 ml of breath fluid was produced 102 
on average. The samples were placed in aliquots and immediately stored on dry ice at -80 degrees 103 
Celsius until analysis.  104 
 105 
2.3 Sample preparation  106 
Samples were thawed on ice and 80 µL of -20°C-cold acetonitrile:methanol (ACN:MeOH, 1:1, v/v) 107 
containing chlorpropamide as internal standard (1 µg/mL) were added to 20 µL EBC. Samples were 108 
shortly vortexed and stored at -80 °C for 30 minutes to precipitate proteins. Afterwards, the samples 109 
were centrifuged in two consecutive steps (14'000 g at 4 °C for 20 min) to remove precipitates and 110 
subsequently, the supernatants were transferred to total-recovery LC-MS glass vials (Waters, Milford, 111 
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MA, USA). A pooled quality control (QC) sample was prepared by mixing 25 µL of individual EBC 112 
sample extracts.  113 
 114 
2.4 Non-targeted metabolomics analysis 115 
Non-targeted metabolomics analysis was performed on a 2D-UPLC I-Class system coupled to a 116 
quadrupole time-of-flight mass spectrometer (Synapt G2-S HDMS, Waters) operated in positive and 117 
negative electrospray ionization (ESI) mode. The mobile phases A and B consisted of 0.1% (v/v) 118 
formic acid in (A) 1% (v/v) MeOH in H2O and (B) MeOH, respectively. The sample injection volume 119 
was 2 µL and the chromatographic separation was performed on an ACQUITY UPLC HSS T3 column 120 
(1.0 mm x 100 mm, 1.8 µm, Waters) by applying a solvent gradient from 100% A to 1% A over 11 121 
min starting at 1 min. The solvent flow rate was set to 0.17 ml/min, the column temperature to 50°C, 122 
and the autosampler to 6°C. Standard mass spectrometric parameters were 0.5 kV and 50 V for 123 
capillary voltage and cone voltage, respectively. Desolvation and source temperature were kept at 124 
450°C and 120°C, respectively. Cone and desolvation flows were set to 150 L/h and 800 L/h, 125 
respectively. Leucine-Enkephalin ([M+H]+ m/z = 556.2766, [M-H]- m/z = 554.2620) was acquired 126 
every 20 s for lock mass correction. Mass spectra were acquired at a scan time of 0.2 s in the MSe 127 
resolution mode over a range of m/z 50-1200. The samples were analyzed with MSe continuum 128 
experiments in the positive and negative electrospray ionization (ESI) mode. The pooled QC sample 129 
was analyzed with a DDA experiment to obtain MS/MS spectrum information. A system suitability 130 
test (SST) containing standards was measured at the beginning and the end of the analytical run to 131 
ensure retention time stability, intensity stability and mass error ≤ 8 ppm. The system was equilibrated 132 
by injecting 10 times the pooled QC sample and at least 10 QC samples were analyzed in each 133 
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analytical batch. The instrument was controlled via MassLynx (version 4.1, Waters). Representative 134 
base peak ion (BPI) chromatograms of a control and a IPF patient EBC sample are presented in figure 135 
1. The pilot study set was analyzed with one replicate per IPF patient and healthy control sample, 136 
whereas for the validation set, duplicate analysis was applied.  137 
 138 
2.5 Data processing and statistical analysis  139 
In step I, the raw mass spectrometric data were imported and processed with Progenesis QI (version 140 
2.2, Nonlinear Dynamics, Newcastle, UK). After lock-mass correction and chromatographic 141 
alignment, ion patterns were deconvoluted between 0.45 – 11 min. As possible ions, [M+H]+, 142 
[M+Na]+, [M+K]+, [M+H-H2O]
+, [M+H-2H2O]
+, [M+2H]2+, [M+3H]3+, [2M+H]+, [2M+Na]+ and 143 
[2M+K]
+
 were defined in the positive mode, and [M-H]
-
, [M-H-H2O]
-
, [M-2H]
2-
, [M-3H]
3-
,
 
144 
[M+HCOOH-H]
-
 and [2M-H]
-
 in the negative mode. Abundances of metabolic features were 145 
normalized to all compounds. Noise reduction was performed by excluding ion patterns from further 146 
analysis with a 2-fold higher abundance in blank versus QC samples, a peak width < 0.05 min, ion 147 
charge > 1 and a coefficient of variation (CV) of the peak area > 30% in the QC samples, as 148 
recommended by Dunn and colleagues [25]. Furthermore, the chromatographic window was specified 149 
between 0.5 – 10.5 min and low abundant metabolic features (normalized abundance < 100, arbitrary 150 
threshold) were excluded. In step II, normalized abundances of the remaining features were subjected 151 
to multivariate analysis with SIMCA (version 14, Umetrics, Umeå, Sweden) for biomarker discovery. 152 
For the validation set, the features abundances of the duplicate analysis were averaged. After Pareto 153 
scaling, principle component analysis (PCA) was performed to visualize trends and detect outliers 154 
among observations in the scores plot. PCA was followed by orthogonal partial least square 155 
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discriminant analysis (OPLS-DA) including model cross-validation to compare discriminant features 156 
between healthy controls and IPF patients. Results were further integrated if the 10-fold cross-157 
validated correlation R2(cum) and Q2(cum) were ≥ 0.5, if the cross validatory ANOVA p-value was ≤ 158 
0.05 and if the permutation test was passed (20 permutations, R2>R2permutation and Q
2
permutation < 0) [26] 159 
[27]. The VIP-plot was used to find discriminative metabolite candidates having a loading vector 160 
p(corr) < -0.5 or > 0.5 and a VIP score of > 1.5. All possible ion features were removed if they were 161 
not significant (i.e., confidence interval crossed zero) within model cross-validation. In step III, 162 
univariate statistical analysis was performed to consistently evaluate the filtered metabolic features. 163 
For the pilot study, pairwise comparisons of continuous variables were carried out with arc-sinh 164 
transformed normalized abundances in the Progenesis QI software. For the validation study, log10 165 
transformed normalized abundances were used in the SIMCA software. Nominal two-sided p-values < 166 
0.05 were considered statistically significant and corrections for multiple testing were done using the 167 
false discovery rate (FDR) method by Benjamini and Hochberg [28]. 168 
In step IV, each potential metabolite candidate was reviewed for its ion alignment and 169 
chromatographic peak shape. In step V, the selected metabolites were searched against the Human 170 
Metabolome Database (HMDB, version 3.6) with a mass accuracy of 8 ppm to obtain potential 171 
structure and formula of the metabolite features. Structure elucidation was performed by comparing 172 
MS/MS spectra from DDA experiments with data from the open source platforms MetFrag [29] and 173 
CSI:FingerID [30] [31].  174 
 175 
3. Results 176 
3.1 Study participants 177 
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In total 10 controls and 10 IPF patients were included in the pilot study set. The baseline 178 
characteristics of the patients are described in table 1. Mean age of controls and IPF patients was 69 179 
and 68 years with a male predominance (9 out of 10). IPF diagnosis was confirmed histologically in 6 180 
out of 10 patients. Pulmonary function tests showed reduced FVC (mean FVC 67% predicted) and 181 
DLCO (mean uncorrected DLCO 43% predicted) in IPF patients. Calculated GAP index (0 to 8 182 
possible score points) ranged from 1 to 6 points (mean 4.2), reflecting GAP stage I to III and a 183 
consecutively increased risk of mortality (predicted 3-year mortality 16% for stage I and 76% for stage 184 
III) [24]. 185 
All except one patient were treated with antifibrotic drugs (Pirfenidone or Nintedanib) for at least three 186 
months before study inclusion. All patients and controls were currently non-smokers, most of them 187 
with a history of cigarette smoking. Basic physical exam and pulmonary functional tests in controls 188 
were normal.  189 
In the validation set, eight IPF patients and healthy controls were included. Healthy control samples 190 
were from additional eight individuals. From IPF patients a new sample was taken two weeks after the 191 
sample of the pilot study. 192 
 193 
3.2 Non-targeted metabolomics analysis 194 
The workflow for measurement, data processing and statistics is illustrated in Figure 2. After data 195 
filtration, 1671 and 981 metabolic features were detected by UHPLC-HRMS in the positive and 196 
negative ionization mode in the pilot study, respectively. The OPLS-DA models only resulted in 197 
acceptable model characteristics in the positive ion mode (table 2). Based on the multivariate analysis, 198 
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26 metabolic features were found to be differentially regulated between healthy controls and IPF 199 
patients. With this approach, only metabolic features with strong model contribution and high 200 
reliability were selected. Univariate statistical analysis was then performed to consistently screen for 201 
additional metabolites. By univariate statistics, 39 metabolic features were significantly regulated in 202 
the positive ion mode. By combination of multivariate and univariate approaches, 58 metabolic 203 
features were found differentially regulated in the pilot study. The profile of the metabolic features 204 
isolated by multivariate and/or univariate statistical analysis revealed a clear discrimination between 205 
the healthy and IPF patients (figure 3, list of regulated metabolic features with the corresponding fold 206 
changes presented in supplementary file 1).  207 
To validate our results, a new set of samples was profiled by UHPLC-HRMS. Similar to the pilot 208 
study, satisfactory multivariate model parameters were only obtained in the positive ionization mode 209 
(table 2). 48 discriminative features were selected by multivariate or univariate analysis (list of 210 
regulated metabolic features with the corresponding fold changes presented in supplementary file 2). 211 
Among them, two metabolic features (m/z 410.3731 and m/z 341.3514 at retention time 10.06 and 9.94 212 
min, respectively) of the pilot study were confirmed. The feature m/z 410.3731 was however regulated 213 
in different direction in both study sets, thus only feature m/z 341.3514 with a retention time of 9.94 214 
min remained consistently more than two-fold up-regulated in IPF patients compared to healthy 215 
controls (figure 4, fold change IPF/healthy of 2.5 in the pilot study and of 2.0 in the validation study, 216 
FDR adjusted p-value ≤ 0.01). The corresponding extracted ion chromatograms of the validated 217 
metabolic feature in the pilot and validation study sets are presented in figure 5.  218 
C21H44N2O was obtained as potential molecular formula for the regulated metabolic feature. The 219 
measured isotope ratio of m/z 341.3514 was in excellent agreement with the simulated one of 220 
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C21H44N2O (98.4% similarity). The major fragment detected by MS/MS experiment (DDA 221 
experiment, m/z = 128.1076, supplementary figure 1) could be assigned to C7H14NO
+
 (with 0.8 ppm 222 
error), which could fit with the suggested formula of the parent ion. Based on the accurate m/z ratio, 223 
possible identities were searched against HMDB and METLIN databases for the validated metabolic 224 
feature m/z 341.3514. No reasonable metabolite was found against these databases by assuming a 225 
protonated [M+H]+ ion. Possible identifications against the databases ChemSpider including 226 
PubChem and MassBank are shown in the supplementary file 3. None of these identifications reflect a 227 
known biologically relevant molecule. 228 
 229 
4. Discussion 230 
In this study, we found 58 metabolic features that discriminated EBC of IPF patients from EBC of 231 
healthy controls in a pilot study set. These discriminative features were isolated by UHPLC-HRMS in 232 
the positive ionization mode. Among them, one metabolic feature (m/z 341.3514 at a retention time of 233 
9.94 min) was up-regulated in IPF patients (FC 2.5) and was validated in an independent set of 234 
samples. It is tenable that this metabolic feature is not related to a drug or a drug metabolite, because it 235 
was also detected in the healthy controls. C21H44N2O was found as a potential molecular formula and 236 
might represent a potential biomarker for IPF from non-invasively collected biofluids for diagnosis. 237 
Further work will be required to identify its structure.  238 
Previous studies on EBC from IPF patients showed promising results. Docosatetraenoyl 239 
lysophosphatitic acid (LPA 22:4), isoprostane and H2O2 were elevated in IPF compared to healthy 240 
controls [32, 33]. In our metabolic study, LPA 22:4 was not detected. This may be due to the lower 241 
sensitivity of our methodology compared to the targeted LC-MS/MS assay used by Montesi et al. [32]. 242 
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EBC has many advantages over other biofluid sampling methods. Collection is simple, non-invasive, 243 
cheap and can be repeated as often as desired. Opposed to induced sputum sampling or BAL it is 244 
nearly always safe even in severely respiratory limited patients. These advantages make EBC a 245 
promising new tool to investigate lung diseases. Given the possibility of sampling at any point of 246 
disease state, EBC can provide a real-time assessment of pulmonary pathologies. Nevertheless, this 247 
technique has several pitfalls: collecting and measuring EBC needs to be standardized in order to 248 
reduce the effect of confounders on data collection and interpretation and to ensure reproducibility. 249 
Recent reviews show high variation in the sampling of EBC due to limited standardization [8, 9]. 250 
Some aspects of collecting EBC can be easily standardized for example the material of the collecting 251 
tube, the temperature of the collecting device and the duration of collection. However, conditions like 252 
ventilation parameters and the degree of dilution vary between subjects and are impossible to 253 
standardize but must be taken into account when interpreting and comparing EBC results [10]. We 254 
recognize this limitation and further investigations are needed to define the influence of ventilation 255 
parameters and the degree of dilution on the molecular profile of EBC. Sampling methods and storage 256 
after collection need to be standardized to improve sample reliability [10]. Recently, after submission 257 
for this study, a proposed standardization for EBC collection has been published and hopefully will 258 
help to improve data about EBC [34]. Overall, poor reproducibility, a lack of large representative 259 
studies and the absence of large norm reference cohorts hinder EBC to enter clinical practice [22]. 260 
EBC has already been investigated by liquid chromatography mass spectrometry (LC-MS) in several 261 
lung diseases, for example in chronic obstructive pulmonary disease (COPD) [13, 21]. Although 262 
smaller clinical trials must be confirmed by larger studies, LC-MS seems to be a promising strategy in 263 
investigating EBC of other lung diseases [13, 23] [35] and our results contribute to the current body of 264 
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evidence. By UHPLC-HRMS a large amount of data are being generated. Artefact peaks can result in 265 
false positives and over-interpretation can bias the results especially in limited sample sets. By 266 
validating a single metabolic feature over the 58 regulated features isolated in the pilot study, we 267 
demonstrated the importance of a validation set for such an analysis. The discovery of new candidate 268 
biomarkers might eventually lead to clinical tools for diagnosis and monitoring of lung diseases. 269 
Nevertheless, molecular biomarkers should reflect relevant pathobiological processes and mechanisms 270 
of a disease. Using screening methods as we did, carries a risk of detecting markers of physiological 271 
processes that have questionable pathobiological importance, and the relevance of many biomarkers in 272 
IPF is not yet clearly defined [36]. However, new non-invasive biomarkers are urgently needed. 273 
5. Conclusions 274 
Our study showed that metabolic profiling by UHPLC-HRMS can be applied to investigate EBC as a 275 
novel matrix for IPF biomarker discovery. We showed distinctive differences in the molecular profile 276 
of EBC from IPF patients compared to healthy controls. Our results should still be confirmed in a 277 
larger cohort and further studies might be able to confirm a profile of biomarkers, that could contribute 278 
to IPF diagnosis, disease state assessment, prediction of disease progression and response to therapy.  279 
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Figure legends 425 
Figure 1: 426 
Representative base-peak ion (BPI) chromatogram in positive ion mode of an EBC sample from 427 
control (upper panel) and IPF patient (lower panel). *Individual differences (Single detection) 428 
**Chromatographic region with accumulation of similar as well as differentially regulated metabolites 429 
between IPF patients and healthy controls. 430 
Figure 2: 431 
Workflow for sample measurement, data processing and statistical analysis. 432 
Figure 3:  433 
Heat map representing the log10-transformed abundance profile of the regulated metabolic features 434 
isolated by multivariate and/or univariate statistical analysis in the pilot study sample set. Identity 435 
(summarized by the retention time followed by the corresponding m/z ratio or neutral mass n) of the 436 
metabolic features are shown on the right side, individual samples in rows, respectively. Cells colored 437 
in red represent up-regulated, colored in blue down-regulated abundances. The analysis was done with 438 
the MetaboAnalyst online platform [37]. 439 
Figure 4: 440 
Distribution of the validated metabolic feature m/z 341.3514 eluting at 9.94 min in the pilot (left) and 441 
validation (right) study sets (standardized abundance, FDR adjusted p-value < 0.05) between controls 442 
and IPF patients in positive ion mode.  443 
 444 
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Figure 5: 445 
Extracted ion chromatograms of the metabolic feature m/z 341.3514 eluting at 9.94 min detected in the 446 
healthy (pink) and IPF (dark blue) patients in the pilot (left) and validation (right) study sets. 447 
  448 
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Table 1. Baseline characteristics of controls and IPF patients. Showing either mean ± standard 449 
deviation or number and percentage of total.  450 
 Controls n=10  IPF patients n=10 
      
Age (years) 68.70 ± 7.91 10 68.44 ± 9.08 10 
Men n (%) 9 (90) 10 8 (88.9) 9 (90) 
      
UIP pattern     
HRCT scan - - 8 10 
Pathology - - 6 10 
     
Pulmonary functional tests     
FVC, L 4.14 ± 0.40 10 2.43 ± 0.49 10 
FVC (% predicted) 114.60 ± 8.49 10 65.1 ± 11.27 10 
DLCO uncorr. (% perdicted) 129.60 ± 31.10 10 43 ±15.02 10 
     
GAP Index score (0-8) - - 4.2 ± 1.4 10 
     
Smoking habits     
Current Smokers n (%) 0 10 0 10 
Former Smokers n (%) 8 (80) 10 7 (77.8) 9 
Pack years 5.50 ± 5.72 8 25.37 ± 15.18 8 
     
Antifibrotic therapy     
Pirfenidon n (%) - - 6 (66.7) 10 
Nintedanib n (%) - - 2 (22.2) 10 
No antifibrotic therapy n (%) - - 1 (11.1) 10 
 451 
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Table 2. Characteristics of the OPLS-DA models for the pilot and validation study sets analysed in positive (ESI+) and negative (ESI-) ion mode. 452 
Sample Set Amount of features  R
2
(cum) Q
2
(cum)
a
 Permutation test (n=20) CV-ANOVA p-value 
Pilot ESI+ 1671 0.896 0.626 R
2
 = 0.535 
Q
2 
= -0.78 
0.03 
Pilot ESI- 981 0.605 0.254 R
2
 = 0.357 
Q2 = -0577 
0.32 
Validation ESI+ 906 0.693 0.544 R
2
 = 0.301 
Q
2
 = -0.479 
0.05 
Validation ESI- 220 0.646 -0.112 R
2
 = 0.537 
Q2 = -0.41 
1 
R
2
 (cum), cumulative sum of squares explained by all extracted components; Q
2
 (cum), cumulative fraction of the predicted variation; 453 
a
 cross validation groups n = 10 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
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Figure 1: 465 
 466 
 467 
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Figure 2: 468 
 469 
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Figure 3  470 
 471 
 472 
  473 
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Figure 4 474 
 475 
Figure 5 476 
 477 
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